New onset migraine with aura after treatment initiation with ivabradine
Background Migraine with aura is a complex neurological disorder modeled in animals by cortical spreading depression. It is less usual to find complete animal models for the disease so any opportunity to test a human effect back at the bench is welcome. Findings We report the case of a 24 year old w...
Gespeichert in:
Veröffentlicht in: | Journal of headache and pain 2013-05, Vol.14 (1), p.45-45, Article 45 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background
Migraine with aura is a complex neurological disorder modeled in animals by cortical spreading depression. It is less usual to find complete animal models for the disease so any opportunity to test a human effect back at the bench is welcome.
Findings
We report the case of a 24 year old woman who developed new onset episodic migraine with visual aura shortly after treatment initiation with the I
f
ion channel blocker ivabradine for frequency control in hypertrophic cardiomyopathy. We studied whether ivabradine could alter cortical spreading depression in a suitable animal model. Sixteen rats received either ivabradine or saline, and the number of depolarization shifts and blood flow changes induced by cortical spreading depression were measured in both groups. No significant differences between the ivabradine and saline group were detected.
Conclusions
Ivabradine is an interesting substance since it is known to produce migraine-like phosphenes frequently and the patient we report developed
de novo
migraine with aura. However, we were unable to demonstrate that the drug influences the susceptibility of the brain to cortical spreading depression with acute administration. The combined data show the relationship of migraine aura to cortical spreading depression may have some nuances yet to be identified. |
---|---|
ISSN: | 1129-2369 1129-2377 1129-2377 |
DOI: | 10.1186/1129-2377-14-45 |